Bilastine
| Bilastine | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 463.60 g/mol [1] |
| Predicted LogP | 2.3 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C28H37N3O3 |
| IUPAC name | 2-[4-[2-[4-[1-(2-ethoxyethyl)benzimidazol-2-yl]piperidin-1-yl]ethyl]phenyl]-2-methylpropanoic acid |
| SMILES | CCOCCN1C2=CC=CC=C2N=C1C3CCN(CC3)CCC4=CC=C(C=C4)C(C)(C)C(=O)O |
| InChI | InChI=1S/C28H37N3O3/c1-4-34-20-19-31-25-8-6-5-7-24(25)29-26(31)22-14-17-30(18-15-22)16-13-21-9-11-23(12-10-21)28(2,3)27(32)33/h5-12,22H,4,13-20H2,1-3H3,(H,32,33) |
| InChIKey | ACCMWZWAEFYUGZ-UHFFFAOYSA-N |
| CAS number | 202189-78-4 |
| UNII | PA1123N395 |
| PubChem CID | 185460 |
| Pharmacokinetics[] | |
|---|---|
| Onset | 1 hour (Allertine) |
| Elimination half-life | 14.5 hours |
| Duration of action | 24 hours (Allertine) |
| Metabolism | Not significantly metabolised |
| Excretion | 95% in urine and faeces |
| Routes of administration | By mouth |
Bilastine (also known as Ilaxten, Bilastina, Bilastinum, R06ax29, Bilaxten, Gtpl11579, Bs-15792, Bilasten, Bilatex or Bilastine?) is a substance of the phenethylpiperidine class.
Chemistry
Stereochemistry []
Bilastine is achiral.
Druglikeness
Lipinski's rule of five
Bilastine matches Lipinski's rule of five.Pharmacology
ATC Classification
- respiratory system (R)
- antihistamines for systemic use (R06)
- antihistamines for systemic use (R06A)
- other antihistamines for systemic use (R06AX)
- (R06AX29)
- bilastine (R06AX29)
- sensory organs (S)
- ophthalmologicals (S01)
- decongestants and antiallergics (S01G)
- other antiallergics (S01GX)
- bilastine (S01GX13)
Mechanism of action []
Bilastine is a selective histamine H1 receptor antagonist (Ki = 64nM). During allergic response mast cells undergo degranulation which releases histamine and other subastances. By binding to and preventing activation of the H1 receptor, bilastine reduces the development of allergic symptoms due to the release of histamine from mast cells. [1]
Interactions []
Subjective effects []
| 0xea / Bilastine [] | |
|---|---|
Routes:
| |
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 185460, Bilastine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/185460
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Bilastine. UNII: PA1123N395. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/PA1123N395
Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025. Therapeutic Goods Administration (TGA). May 2025. https://www.legislation.gov.au/F2025L00599/asmade/2025-05-28/text/original/pdf
Health Canada New Drug Authorizations: 2016 Highlights. Health Canada. 14 March 2017. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2016-highlights.html
bilastine classification. (mcc). https://medsafe.govt.nz/profs/class/classintro.asp
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 13:51:31 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 13:51:27 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 13:51:27 |
| gsrs | ok | 2026-11-20 13:51:27 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0240232) | 2026-11-20 13:51:27 |
| kegg | ok | 2026-11-20 13:51:28 |
| pubchem | ok | 2026-11-20 13:51:27 |
| missing (no r/tripreports posts mention it) | 2026-11-20 13:51:27 | |
| sider | missing (not in SIDER) | 2026-11-20 13:51:27 |
| structure | ok | 2026-11-20 13:51:27 |
| wikipedia | ok | 2026-11-20 13:51:27 |